Mutational signature dynamics indicate SARS-CoV-2's evolutionary capacity is driven by host antiviral molecules
Kieran D. Lamb,Martha M. Luka,Megan Saathoff,Richard J. Orton,My V. T. Phan,Matthew Cotten,Ke Yuan,David L. Robertson
DOI: https://doi.org/10.1371/journal.pcbi.1011795
2024-01-26
PLoS Computational Biology
Abstract:The COVID-19 pandemic has been characterised by sequential variant-specific waves shaped by viral, individual human and population factors. SARS-CoV-2 variants are defined by their unique combinations of mutations and there has been a clear adaptation to more efficient human infection since the emergence of this new human coronavirus in late 2019. Here, we use machine learning models to identify shared signatures, i.e., common underlying mutational processes and link these to the subset of mutations that define the variants of concern (VOCs). First, we examined the global SARS-CoV-2 genomes and associated metadata to determine how viral properties and public health measures have influenced the magnitude of waves, as measured by the number of infection cases, in different geographic locations using regression models. This analysis showed that, as expected, both public health measures and virus properties were associated with the waves of regional SARS-CoV-2 reported infection numbers and this impact varies geographically. We attribute this to intrinsic differences such as vaccine coverage, testing and sequencing capacity and the effectiveness of government stringency. To assess underlying evolutionary change, we used non-negative matrix factorisation and observed three distinct mutational signatures, unique in their substitution patterns and exposures from the SARS-CoV-2 genomes. Signatures 1, 2 and 3 were biased to C→T, T→C/A→G and G→T point mutations. We hypothesise assignments of these mutational signatures to the host antiviral molecules APOBEC, ADAR and ROS respectively. We observe a shift amidst the pandemic in relative mutational signature activity from predominantly Signature 1 changes to an increasingly high proportion of changes consistent with Signature 2. This could represent changes in how the virus and the host immune response interact and indicates how SARS-CoV-2 may continue to generate variation in the future. Linkage of the detected mutational signatures to the VOC-defining amino acids substitutions indicates the majority of SARS-CoV-2's evolutionary capacity is likely to be associated with the action of host antiviral molecules rather than virus replication errors. We show that both public health measures and virus properties are associated with the rise and fall of regional SARS-CoV-2 reported infection numbers with regional differences attributable to the extent of vaccine usage and the effectiveness of public health measures. In our mutational signature analysis, using non-negative matrix factorisation, we detected three distinct mutational signatures that can be putatively attributed to the action of specific host antiviral molecules. Interestingly, we observe a shift in mutational signature activity from predominantly Signature 1 changes to an increasingly high proportion of changes consistent with Signature 2. These mutation patterns influence SARS-CoV-2's evolutionary capacity, the available genetic variation that selection can act on, and so can be linked to the mutations defining the variants of concern responsible for the distinct SARS-CoV-2 infection waves. The dominant types of nucleotide substitutions involved indicate that much of the mutation and hence variation come from the action of the host immune response rather than replication errors since the virus has an error correction system.
biochemical research methods,mathematical & computational biology